Oxybutynin treatment for buprenorphine-naloxone-induced hyperhidrosis
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
UMass Chan Affiliations
School of MedicineDocument Type
Journal ArticlePublication Date
2021-01-11Keywords
buprenorphine-naloxonehyperhidrosis
opioid agonists
opioid antagonists
opioid use disorder
oxybutynin
suboxone
Dermatology
Skin and Connective Tissue Diseases
Substance Abuse and Addiction
Metadata
Show full item recordAbstract
Hyperhidrosis occurs when sweating is excessive for thermoregulatory purposes, which may result in decreased quality of life and emotional stress for patients.Classified as primary and secondary, secondary hyperhidrosis is often related to an underlying cause. Certain medications have been reported to induce hyperhidrosis, including selective serotonin reuptake inhibitors, tricyclic antidepressants, and opioid agonists. We present the case of a woman with a history of opioid use disorder who experienced hyperhidrosis in the setting of partial opioid agonist and opioid antagonist therapy (buprenorphine-naloxone), who was treated successfully with oral oxybutynin 5 mg daily.Source
McCormack L, Ponce J, Chatterjee A, Tan JK. Oxybutynin treatment for buprenorphine-naloxone-induced hyperhidrosis. JAAD Case Rep. 2021 Jan 11;10:22-24. doi: 10.1016/j.jdcr.2020.12.031. PMID: 33732840; PMCID: PMC7941000. Link to article on publisher's site
DOI
10.1016/j.jdcr.2020.12.031Permanent Link to this Item
http://hdl.handle.net/20.500.14038/41885PubMed ID
33732840Related Resources
Rights
Copyright © 2021 by the American Academy of Dermatology, Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Distribution License
http://creativecommons.org/licenses/by-nc-nd/4.0/ae974a485f413a2113503eed53cd6c53
10.1016/j.jdcr.2020.12.031
Scopus Count
Collections
Except where otherwise noted, this item's license is described as Copyright © 2021 by the American Academy of Dermatology, Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

